Perrigo Wisconsin, LLC – FDA Warning Letter, Apr 26, 2023
The FDA inspected Perrigo's Gateway infant formula manufacturing facility from March 6 to April 26, 2023, identifying significant violations of 21 C.F.R. Part 106 (Infant Formula Rule) and the Federal Food, Drug, and Cosmetic Act. Key deficiencies included a failure to establish adequate process controls to prevent microbial adulteration (21 C.F.R. § 106.55(a)). The inspection revealed repeated Cronobacter spp. positives in finished products across multiple campaigns and persistent Cronobacter sakazakii in environmental samples, indicating resident pathogens and inadequate sanitation procedures. Root cause investigations were found lacking, specifically in the absence of Whole Genome Sequencing (WGS) for isolates and immediate sanitation without pre-clean swabbing. The firm's environmental monitoring program was deemed insufficient, failing to detect pathogens for months and over-relying on Enterobacteriaceae monitoring. Additionally, Perrigo failed to promptly notify FDA of adulterated infant formula (Gerber Good Start Soothe Pro) released into interstate commerce, violating 21 C.F.R. § 106.150. While Perrigo submitted a corrective action plan, FDA requires further actions, including a thorough evaluation of sanitation in product disposition and comprehensive root cause analyses for persistent pathogens. The company must respond within 15 working days, detailing corrective steps to avoid potential legal action.
- Company
- Perrigo Wisconsin, LLC
- Inspection date
- April 26, 2023
ID · 1c112226-98a7-443a-8a27-19afbdb853d4
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.